State Street Corp Raises Position in Delcath Systems, Inc. (NASDAQ:DCTH)

State Street Corp raised its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 12.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 85,457 shares of the company’s stock after acquiring an additional 9,400 shares during the period. State Street Corp’s holdings in Delcath Systems were worth $772,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Delcath Systems during the 3rd quarter valued at about $102,000. Riverwater Partners LLC purchased a new stake in Delcath Systems in the third quarter valued at approximately $161,000. Cubist Systematic Strategies LLC bought a new stake in Delcath Systems during the second quarter valued at approximately $370,000. Renaissance Technologies LLC bought a new stake in Delcath Systems during the second quarter valued at approximately $694,000. Finally, Marshall Wace LLP grew its stake in Delcath Systems by 7.0% in the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after buying an additional 6,066 shares in the last quarter. 61.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on DCTH shares. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Stock Up 4.7 %

Shares of NASDAQ:DCTH opened at $12.61 on Friday. The stock has a market cap of $403.19 million, a PE ratio of -9.34 and a beta of 0.85. The company’s fifty day moving average is $11.01 and its 200 day moving average is $9.54. Delcath Systems, Inc. has a 52 week low of $3.70 and a 52 week high of $13.30.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.